- Severe disorders with devastating and life-threatening medical consequences
- Disorders with ineffective, or no treatment options
- Disorders that are ultra-rare and affect very small numbers of patients
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
Ludwig Hantson takes over the top Alexion job after serving as CEO of Baxalta, which he helped sell to Shire for $32 billion.
Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.